DAVITA INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $DVA in the last 30 days.
See all $DVA insider activity →DaVita Inc. agreed to pay up to $15M to resolve a class-action lawsuit over a 2025 ransomware attack. The settlement, pending final approval, covers cash payouts, documented losses, and credit monitoring for affected patients. DaVita denies liability. The case is closely watched in the healthcare sector.
DaVita (DVA) expanded its partnership with Humana to manage Medicare Advantage members with early-stage chronic kidney disease. The stock has dropped 26.64% in 30 days but gained 53.82% year-to-date and 82.25% over three years. Analysts estimate a fair value of $218.43, suggesting the stock is undervalued at its current price of $176.14. Management highlights investments in technology and AI to drive efficiency and margin improvements.
Berkshire Hathaway reduced its stake in Capital One by 58% in Q2 2026, according to its 13F filing. The company cut its position from 7.15 million to 3 million shares. Capital One, which has a high growth score, saw its stock fall 12.61% year-to-date. Meanwhile, Third Point LLC increased its stake in Capital One, citing strong earnings.
Over the past 7 days, alphai's AI scored 3 news stories mentioning DVA (DAVITA INC.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 1 bearish.
Recent DVA coverage spans financial news, corporate actions and earnings.
Potential liability and cash outflow may pressure DaVita's stock, though the settlement cap limits exposure.
The partnership could boost DaVita's revenue pipeline and support margin improvement, potentially narrowing the valuation gap.
Small stake reduction unlikely to move the stock.
Earnings beat and higher guidance suggest near‑term upside.
The partnership expands DaVita's services upstream in the kidney‑care continuum.
alphai scores every news story that mentions DVA with an AI model for sentiment and relevance, and aggregates insider trades from DAVITA INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DaVita Inc. agreed to pay up to $15M to resolve a class-action lawsuit over a 2025 ransomware attack. The settlement, pending final approval, covers cash payouts, documented losses, and credit monitoring for affected patients. DaVita denies liability. The case is closely watched in the healthcare sector.
2 min readDaVita (DVA) expanded its partnership with Humana to manage Medicare Advantage members with early-stage chronic kidney disease. The stock has dropped 26.64% in 30 days but gained 53.82% year-to-date and 82.25% over three years. Analysts estimate a fair value of $218.43, suggesting the stock is undervalued at its current price of $176.14. Management highlights investments in technology and AI to drive efficiency and margin improvements.
2 min readBerkshire Hathaway reduced its stake in Capital One by 58% in Q2 2026, according to its 13F filing. The company cut its position from 7.15 million to 3 million shares. Capital One, which has a high growth score, saw its stock fall 12.61% year-to-date. Meanwhile, Third Point LLC increased its stake in Capital One, citing strong earnings.
2 min readBerkshire Hathaway's largest proportional holding is in DaVita (DVA), a kidney dialysis center operator, with a 45% stake. Berkshire has reduced its position from 36.1 million to 28.7 million shares since early 2025. DaVita's stock is up 56% year-to-date, with Q1 revenue of $3.4 billion and adjusted profit of $198 million. The company raised its EPS guidance to $14.10-$15.20.
2 min readDaVita (DVA) expanded its value-based care agreement with Humana to cover 10,000 Medicare Advantage members with chronic kidney disease. The deal aims to engage patients earlier and integrate comprehensive care. While it may improve earnings quality, its financial impact is expected to be modest. DaVita's shares have risen but remain sensitive to debt and reimbursement risks, with fair value estimates ranging from $218 to $453.
3 min readBerkshire Hathaway (BRK.A, BRK.B) shifted to net stock buying in Q2 2026, contrasting Warren Buffett's cash-hoarding stance. Under Greg Abel, it bought Alphabet ($17B), Delta ($1.64B), Lennar ($273M), and Macy's ($101M), while selling Bank of America ($1.7B) and others. Buffett still views the market as overvalued, per a May CNBC interview.
3 min readDaVita Inc. and Humana Inc. have formed a value-based care agreement to provide coordinated care for Medicare Advantage members with chronic kidney disease. The partnership, effective July 1, aims to improve patient outcomes and reduce hospital admissions by addressing cardiovascular, kidney, and metabolic health. DaVita's network of 3,000 nephrologists will support over 10,000 patients, focusing on early intervention and comprehensive care.
2 min readDaVita (DVA) reported an insider stock transaction. A director acquired 278 shares of common stock and disposed of 14,021 shares indirectly. The transaction occurred on August 15, 2026, according to the SEC filing.
1 min readDaVita (DVA) reported that director Phyllis R. Yale received a grant of 278 shares of common stock on 2026-08-15, with no transaction price. She now directly holds 9,803 shares. The filing did not report any sales or derivative transactions.
1 min readDaVita (DVA) director Adam H. Schechter received a grant of 278 shares of Common Stock on August 15, 2026, at $0.00 per share, increasing his direct holdings to 5,970 shares. The transaction was reported as a Form 4 award.
1 min read
